We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+23.92%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$210M
Cap. Flow
+$121M
Cap. Flow %
19.85%
Top 10 Hldgs %
60.54%
Holding
32
New
6
Increased
15
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$41.1M
2
OPCH icon
Option Care Health
OPCH
+$27.7M
3
CADX
CADENCE PHARMACEUTICALS, INC COM STK
CADX
+$18.8M
4
ENDP
Endo International plc
ENDP
+$16.6M
5
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$15.6M

Top Sells

Rank Stock Value
1
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$43.1M
2
AFFX
Affymetrix Inc
AFFX
+$21.3M
3
BIIB icon
Biogen
BIIB
+$14.4M
4
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$4.64M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$4.05M

Sector Composition

Rank Sector Weight
1 Healthcare 77.88%
2 Miscellaneous 22.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
26
Vanda Pharmaceuticals
VNDA
$311M
$1.29M 0.21%
104,000
-403,469
-80% -$4.05M
ARIA
27
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$84K 0.01%
12,260
-292,200
-96% -$1.58M
BIIB icon
28
Biogen
BIIB
$32.1B
– –
-60,000
Closed -$14.4M
HZNP
29
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-105,000
Closed -$352K
AFFX
30
DELISTED
Affymetrix Inc
AFFX
– –
-3,442,140
Closed -$21.3M
NPSP
31
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-1,355,152
Closed -$43.1M
CELGZ
32
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
– –
-13,770
Closed -$111K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Consonance Capital Management held 32 positions worth $610M, up 53% from $400M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Consonance Capital Management deployed $121M of net new capital in Q4 2013, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Aegerion Pharmaceuticals: 537,034 shares worth $38.1M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $4.64M trimmed.

  • Consonance Capital Management's largest Q4 2013 buy was Aegerion Pharmaceuticals: 537,034 shares worth $38.1M.
  • Consonance Capital Management added most to Endo International plc in Q4 2013, an estimated $16.6M increase.
  • Consonance Capital Management's biggest Q4 2013 reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $4.64M.
  • Consonance Capital Management fully exited NPS PHARMACEUTICALS INC in Q4 2013, selling an estimated $43.1M.
  • Consonance Capital Management's ten largest holdings make up 61% of its $610M portfolio in Q4 2013.
  • Consonance Capital Management opened 6 new positions and closed 5 in Q4 2013.
  • Consonance Capital Management's portfolio value rose 53% quarter-over-quarter to $610M.

Based on Consonance Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.